ImmunityBio Inc.

14 days ago · benzinga.com

A recent study published in the Journal of Urology revealed promising long-term results for ImmunityBio, Inc. (NASDAQ:IBRX) and its immunotherapy treatment, ANKTIVA.

17 days ago · businesswire.com

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Highl.

18 days ago · zacks.com

IBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.

18 days ago · benzinga.com

ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Thursday after the FDA expanded the approved indication for its bladder cancer immunotherapy ANKTIVA to include BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors.

25 days ago · businesswire.com

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate virtually in a fireside chat at the Piper Sandler Virtual Oncology Symposium, taking place October 15-16, 2026. Details of the event are provided below: Piper Sandler Virtual Oncology Symposium – Fireside Chat Participant: Patrick Soon-Shion.

1 month ago · benzinga.com

ImmunityBio Inc. (NASDAQ:IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.

2 months ago · zacks.com

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

2 months ago · zacks.com

ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?

2 months ago · seekingalpha.com

ImmunityBio is rated a strong buy, driven by ANKTIVA's FDA approval for BCG-unresponsive NMIBC and significant pipeline expansion potential. Current valuation reflects success in bladder cancer and BCG-naïve expansion, but assigns limited value to systemic immunotherapy potential in NSCLC or other types of cancer. Key near-term catalysts include phase 3 NSCLC data and BCG-naïve bladder cancer trial results, both of which could unlock substantial upside.

3 months ago · businesswire.com

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong. The Office of the Executive Chairman will bring together senior leade.